Distinguishing children with potentially life-threatening bacterial infections from febrile children with viral infections remains a major challenge. Herberg and colleagues, 1 in a preliminary, cross-sectional study of 370 febrile children (aged <17 years) in Europe and the United States, reported that children with bacterial infection may be characterized by the difference in blood RNA expression values of 2 genes. In a recent study, Mahajan and colleagues 2 reported a 66-transcript blood
RNA signature that distinguished bacterial from viral infection in 279 febrile infants younger than 60 days. Young infants are at high risk of bacterial infection; diagnosis is difficult and prompt treatment important. To provide further validation of the 2-gene signature and to evaluate its performance in the infant population, we applied the signature to the RNA expression data of Mahajan et al. obtained from a convenience sample of febrile neonates and infants less than 60 days old who were recruited from 22 US emergency departments between 2008 and 2010. Eightynine infants had culture-positive bacterial infections (32 with bacteremia and 57 with urinary tract infection) and 190 had negative bacterial cultures (111 with proven viral infection, 38 not tested for viruses, and 41 with negative test results). After logarithmic transformation, robust spline normalization and quality control using the lumi Bioconductor package in R (R Foundation), version 3.3.1, the expression values for the 2-signature transcripts IFI44L (RefSeq ID: NM_006820.1) and FAM89A (RefSeq ID: NM_198552.1) were extracted for each patient. These values were combined into a single disease risk score (DRS), as described in the study by Kaforou and colleagues, 4 by subtracting the intensity of the IFI44L transcript from the intensity of the FAM89A transcript. We evaluated the predictive accuracy of the DRS first in patients with microbiologically confirmed diagnoses, and then in patients without definite clinical diagnosis. Using the pROC package in R, 5 we calculated the area under the characteristic curve (AUC), sensitivity, specificity, and their 95% CIs under the negative binomial distribution.
Results | When the 2-transcript DRS signature was applied to infants with definite bacterial diagnoses (n = 89) and proven viral infections (n = 111), sensitivity was 88.8% (95% CI, 80.3%-94.5%), specificity was 93.7% (95% CI, 87.4%-97.4%) and AUC was 95.7% (95% CI, 92.6%-98.3%) (Figure) . Discussion | The studies by Herberg et al and Mahajan et al reported sensitivities of 100% (95% CI, 85%-100%) and 87% (95% CI, 73%-95%), respectively, and specificities of 96.4% (95% CI, 89.3%-100%) and 89% (95% CI, 81%-93%), respectively, for the discrimination of bacterial from viral and nonbacterial infections. In this study, the 2-transcript RNA signature, which was originally identified and validated in children with a mean age of 19 months, also had high sensitivity and specificity in the specific population of infants younger than 60 days. The performance of the DRS signature in the groups with uncertain clinical diagnoses should be regarded as exploratory. As bacteria can only be definitively identified as the cause of infection when cultured from normally sterile sites, performance metrics of any new biomarker can only be reliably evaluated in patients with confirmed viral or bacterial infection. However, children with features of bacterial infection but negative cultures are commonly encountered in clinical practice and interpretation of DRS results remains inconclusive. Other limitations include the small number of patients from a limited number of clinical settings.
The 2-gene DRS has the potential to translate into a simple bedside diagnostic test, but further studies in larger cohorts of infants and children representing the broad spectrum of febrile children are needed. 
Comparative Trends in Payment Adjustments Between Safety-Net and Other Hospitals Since the Introduction of the Hospital Readmission Reduction Program and Value-Based Purchasing
The Hospital Readmission Reduction Program (HRRP) penalizes hospitals with higher than expected 30-day readmission rates for select conditions, and Value-Based Purchasing (VBP) adjusts Medicare's payment rate to hospitals based on a set of defined process, outcome, and experience of care measures thereby redistributing dollars collected in penalties to higher performers as bonuses.
1 Because safety-net hospitals historically have higher readmission rates and lower performance on process of care and patient experience measures, there has been concern that these programs put safety-net hospitals at a financial disadvantage. 2,3 Several studies have found that safety-net hospitals are more likely to be penalized under both the HRRP and VBP 4,5 despite improvements in their readmission rates. 6 To assess the current status of these issues, we examined trends in Medicare payment adjustments made to hospitals under these programs since fiscal year (FY) 2013, and underlying changes within different clinical condition categories in the HRRP, with a focus on hospital safety-net status.
Methods | The study analyzed public Centers for Medicare & Medicaid Services (CMS) program data and did not require institutional review board approval. We used each participating hospital's payment adjustments in the HRRP and VBP, publicly available from the CMS, matched with each hospital's disproportionate share payment percentage from the Medicare Impact File. The HRRP and VBP payment adjustments are assessed as a percentage of all Medicare payments a hospital receives. HRRP is based on excess readmission ratios calculated by CMS for specific conditions. Ratios greater than 1 represent worse than expected
